IOME Bio, a seed stage biotechnology company focused on overcoming tumour resistance to immune checkpoint inhibition, has published its foundational research by founders Dr Arlene Sharpe and Dr Dennis Kasper in Nature. By providing evidence of its therapeutic relevance, it reveals insights into the importance of the RGMb/PD-L2 pathway in immunotherapy resistance and further strengthens […]
